Clinical Trials

1,473 enrolled

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT06065748 2026-06-04

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

1,050 enrolled

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT07174336 2026-06-04

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

920 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05038735 2026-06-02

EPIK-B5

210 enrolled

Breast Neoplasms

NCT04862663 2026-05-27

CAPItello-292

895 enrolled

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT03425838 2026-05-20

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

1,050 enrolled

Breast Neoplasm Female

NCT06757634 2026-05-18

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

1,180 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06380751 2026-05-15

EvoPAR-BR01

500 enrolled

Advanced Breast Cancer

NCT06982521 2026-05-08

ReDiscover-2

540 enrolled

Breast Neoplasms

NCT05646862 2026-05-06

INAVO121

420 enrolled

Breast Neoplasms

NCT07062965 2026-05-06

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

400 enrolled

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT04305496 2026-04-30

CAPItello-291

818 enrolled 19 charts 2 FDA

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT05306340 2026-04-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

373 enrolled

Breast Neoplasms

NCT05696626 2026-04-21

ELAINEIII

500 enrolled

Breast Neoplasms

NCT04650581 2026-04-13

FINER

250 enrolled 13 charts

Breast Neoplasms

NCT06764186 2026-04-08

CAPItana

101 enrolled

Breast Neoplasms

NCT04851613 2026-04-02

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

256 enrolled

Breast Neoplasms

NCT06954961 2026-03-31

A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

640 enrolled

Breast Neoplasms

NCT06635447 2026-03-27

CAPItrue

258 enrolled

Breast Neoplasms, Disease Progression

NCT00099437 2026-03-18

CONFIRM

736 enrolled 14 charts

Breast Neoplasms

NCT05654623 2026-03-18

VERITAC-2

624 enrolled 17 charts 1 FDA

Breast Neoplasms

NCT06016738 2026-03-13

OPERA-01

510 enrolled